ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / EVO / earnings
DRUG (46) PBYI (70) NGNE (36) STTK (29) ⌘ Pro Terminal →

Evotec SE (EVO) Next Earnings Date & Expected ±6.9% Move

$1.52 -0.65% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.52

Evotec SE (EVO) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $544.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EVO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EVO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Evotec SE (NASDAQ: EVO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.52 (-0.65% 1D, market cap $544.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, EVO ranks #307 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EVO compare to DRUG and PBYI in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EVO carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DRUG (Bright Minds Biosciences Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $539.9M) and PBYI (Puma Biotechnology Inc) posts a B- grade (70/100 RQD, P/E 17.5x, ROIC 29.3%, cap $538.9M). Among the 5-stock peer group, PBYI leads on earnings multiple (17.5x) while PBYI leads on capital efficiency (29.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EVO?
▼

For Evotec SE (EVO), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #307 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.52 (-0.31%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.4% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510047
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (12)Whales (5)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.3% Base Target
$4 Bull$1 Base$1 Bear
📬 FREE EVO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EVO)Realized 20D OHLCV Swing Band: ±6.9%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY EVO SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0.4% FCF Margin ($15.2M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$1.35+9.6% Next Q
Q2 (-2Q)
42
Grade D$1.48+6.1% Next Q
Q3 (-1Q)
44
Grade D$1.57-3.2% Next Q
Current
47
Grade D$1.52-5.9% Hist 90D α
Trajectory: E (39) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EVO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EVO currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.63) and Max Pain ($1.60) forces dealer call-delta covering toward $4.29.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EVO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “EVO Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 47%NO 53%Trade / Inspect Odds →
NEXT EST. WINDOW: Upcoming Quarter (~28 DAYS)

Historical OHLCV Volatility ±6.9% Swing Band

±$0.10 Expected Swing
$1.42 (-6.9%)Spot $1.52$1.62 (+6.9%)
MODEL EARNINGS SETUP GAUGE

EVO Quantitative Pre-Earnings Setup: 47/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (47/100)Model Risk Weight (53/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EVO)

  • ✓Walkthrough of EVO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
EVO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -51.28%⚡ TESTING RESISTANCE
2026-11-03O $1.58H $1.58L $1.52C $1.52VOL 73.3K
RES: $1.57SUP: $1.16SMA50: $1.63SMA200: $2.50
$3.53$2.94$2.34$1.74$1.14RES $1.57SUP $1.16$1.522026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EVO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EVO Butterfly Map → + Track EVO →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on EVO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EVO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EVO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EVO)

Health Care Rank #307 of 1015 ⚔️ DRUG vs EVO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EVO vs. DRUG, PBYI, NGNE, STTK)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Evotec SE (EVO) ranks #307 by composite RQD confidence (47/100, grade D) and #426 by equity capitalization ($544.3M). Within this direct 5-issuer industry benchmark cohort, PBYI leads on earnings valuation at 17.5x trailing P/E, while PBYI leads on capital efficiency and profitability with 29.3% ROIC and 74.5% gross margin. PBYI currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with EVO at 47/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
EVO ACTIVE
Evotec SE
D 47/100 — — — -0.65% $544.3M Benchmark Subject
DRUG
Bright Minds Biosciences Inc.
D 46/100 — — — -52.35% $539.9M /drug-vs-evo →
PBYI
Puma Biotechnology Inc
B- 70/100 17.5x 74.5% 29.3% -2.49% $538.9M /pbyi-vs-evo →
NGNE
Neurogene Inc.
D- 36/100 — — -35.0% -3.41% $551.3M /ngne-vs-evo →
STTK
Shattuck Labs Inc.
E 29/100 — — -35.0% -4.32% $558.0M /sttk-vs-evo →

2. EVO Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Evotec SE (EVO) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $544.3M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. EVO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EVO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Evotec SE (NASDAQ: EVO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.52 (-0.65% 1D, market cap $544.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, EVO ranks #307 in composite RQD confidence.

How does EVO compare to DRUG and PBYI in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EVO carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DRUG (Bright Minds Biosciences Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $539.9M) and PBYI (Puma Biotechnology Inc) posts a B- grade (70/100 RQD, P/E 17.5x, ROIC 29.3%, cap $538.9M). Among the 5-stock peer group, PBYI leads on earnings multiple (17.5x) while PBYI leads on capital efficiency (29.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EVO?

For Evotec SE (EVO), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #307 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EVO trading relative to its 50-day, 200-day, and 52-week technical levels?

EVO last traded at $1.52 (-0.65% on volume of 67,643 shares), positioning the stock -6.75% below its 50-day simple moving average ($1.63) and -39.20% below its 200-day simple moving average ($2.50). Across its 52-week range of $1.33 to $4.09, EVO sits at the 6.9% percentile with a 14-day RSI of 47.4 (NEUTRAL RANGE) and an implied next-earnings move of ±6.9% ($1.42 to $1.62).

Direct Sub-Reports: EVO RQD Cockpit EVO 12M Forecast EVO Earnings & Move EVO Dividends & DRIP EVO Insiders & 13F EVO Whale Options EVO Profit Sankey EVO News & Why
ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ SEC XBRL & RQD VERIFIED

EVO — Evotec SE: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Evotec SE (EVO) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $1.52 (-0.65% 1D, market capitalization $544.3M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Evotec SE (EVO) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The profile identifies a market capitalization of $0.6B.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 47/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $1.33 – $4.09 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), EVO carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can EVO sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $4.09 52-week high?
  • Key Question #3: How sensitive is EVO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

EVO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Evotec SE (EVO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EVO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EVO Bull vs. Bear Conversation Board — What's Your Call at $1.52?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EVO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on EVO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $2.02 (+32.0%)
📌 Pinned Debate

The forensic balance sheet pillar scores 13 of 20 with an Altman Z of 2.5 and a Piotroski F of 6/9, the strongest component of the rati

Long EVO at $1.53 targeting $2.02. The forensic balance sheet pillar scores 13 of 20 with an Altman Z of 2.5 and a Piotroski F of 6/9, the strongest component of the rating.. Institutional whale score is 5/20 and the risk/reward vs. the $1.33 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

@ForensicBear Shorting a 5/20 institutional whale-flow stock at $1.53 is dangerous when funds are rotating into Health Care.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $1.15 (-24.8%)
Spot @ $1.53

ROIC and FCF yield are both 0% and the stock trades at $1.58, near the lower end of its $1.33 - $4.09 52-week range, with an RQD grade

Sitting on the sidelines or leaning short EVO above $1.53. ROIC and FCF yield are both 0% and the stock trades at $1.58, near the lower end of its $1.33 - $4.09 52-week range, with an RQD grade of D.. Until Fundamental Cash Engine (12/20) and FCF yield (0.0%) inflect higher, upside is capped near $4.09.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%